FR2340318A1 - Nouvelles formes de precurseurs de medicament transitoires, du type derives de xanthine. - Google Patents

Nouvelles formes de precurseurs de medicament transitoires, du type derives de xanthine.

Info

Publication number
FR2340318A1
FR2340318A1 FR7703242A FR7703242A FR2340318A1 FR 2340318 A1 FR2340318 A1 FR 2340318A1 FR 7703242 A FR7703242 A FR 7703242A FR 7703242 A FR7703242 A FR 7703242A FR 2340318 A1 FR2340318 A1 FR 2340318A1
Authority
FR
France
Prior art keywords
transitional
new forms
xanthine derivative
derivative type
drug precursors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7703242A
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interx Research Corp
Original Assignee
Interx Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interx Research Corp filed Critical Interx Research Corp
Publication of FR2340318A1 publication Critical patent/FR2340318A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7703242A 1976-02-06 1977-02-04 Nouvelles formes de precurseurs de medicament transitoires, du type derives de xanthine. Withdrawn FR2340318A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/655,786 US4061753A (en) 1976-02-06 1976-02-06 Treating psoriasis with transient pro-drug forms of xanthine derivatives

Publications (1)

Publication Number Publication Date
FR2340318A1 true FR2340318A1 (fr) 1977-09-02

Family

ID=24630341

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7703242A Withdrawn FR2340318A1 (fr) 1976-02-06 1977-02-04 Nouvelles formes de precurseurs de medicament transitoires, du type derives de xanthine.

Country Status (11)

Country Link
US (1) US4061753A (ref)
AU (1) AU506717B2 (ref)
BE (1) BE851078A (ref)
CA (1) CA1104569A (ref)
DE (1) DE2705025A1 (ref)
FR (1) FR2340318A1 (ref)
GB (1) GB1576351A (ref)
IL (1) IL51367A0 (ref)
IN (1) IN146058B (ref)
SE (1) SE7700971L (ref)
ZA (1) ZA77621B (ref)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189101A3 (en) * 1985-01-23 1987-10-14 PROTER S.p.A. Compounds having mucolytic and bronchodilating activity, a process for their preparation and pharmaceutical composition containing them as active principle
EP0195496A3 (en) * 1985-01-21 1990-01-17 Beecham Group Plc Use of xanthines in the treatment of proliferative skin disease
EP0369744A3 (en) * 1988-11-14 1991-04-10 SMITHKLINE BEECHAM PHARMA GmbH Xanthine derivatives, process for their preparation and pharmaceutical compositions
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4133893A (en) * 1977-05-26 1979-01-09 Calbiochem Behring Corp. Topical treatment of skin diseases
SE416810C (sv) * 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
DE2922159A1 (de) * 1979-05-31 1980-12-04 Boehringer Mannheim Gmbh Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK172081A (da) * 1980-04-21 1981-10-22 Merck & Co Inc Mercaptoforbindelse og fremgangsmaade til fremstilling deraf
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
US4921858A (en) * 1986-10-24 1990-05-01 Warner-Lambert Company 7-deazaguanines as immunomodulators
US5886162A (en) * 1989-11-03 1999-03-23 Research Foundation Of State University Of New York Lipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6541517B1 (en) 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
US6117904A (en) * 1999-09-03 2000-09-12 Murphy; Donald M. Treatment of pruritus
MY133479A (en) * 2001-02-24 2007-11-30 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
RU2196583C1 (ru) * 2001-05-29 2003-01-20 Барбинов Вячеслав Викторович Средство для наружной терапии псориаза и способ его изготовления
JP4233524B2 (ja) * 2002-08-21 2009-03-04 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造およびその薬理組成物としての使用
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1265879A (fr) * 1960-05-23 1961-07-07 Dérivés substitués en -7 de la théophylline et leurs procédés de préparation
DE1226587B (de) * 1962-07-05 1966-10-13 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Theophyllinoaminosaeuren

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195496A3 (en) * 1985-01-21 1990-01-17 Beecham Group Plc Use of xanthines in the treatment of proliferative skin disease
EP0189101A3 (en) * 1985-01-23 1987-10-14 PROTER S.p.A. Compounds having mucolytic and bronchodilating activity, a process for their preparation and pharmaceutical composition containing them as active principle
EP0369744A3 (en) * 1988-11-14 1991-04-10 SMITHKLINE BEECHAM PHARMA GmbH Xanthine derivatives, process for their preparation and pharmaceutical compositions
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines

Also Published As

Publication number Publication date
BE851078A (fr) 1977-05-31
US4061753A (en) 1977-12-06
ZA77621B (en) 1977-12-28
GB1576351A (en) 1980-10-08
AU506717B2 (en) 1980-01-24
SE7700971L (sv) 1977-08-07
IL51367A0 (en) 1977-04-29
DE2705025A1 (de) 1977-08-11
IN146058B (ref) 1979-02-10
AU2202577A (en) 1978-08-17
CA1104569A (en) 1981-07-07

Similar Documents

Publication Publication Date Title
FR2340318A1 (fr) Nouvelles formes de precurseurs de medicament transitoires, du type derives de xanthine.
BE847034A (fr) Derives de piperidyl-triazine.
FI73966B (fi) Foerfarande foer framstaellning av nya cyklopropankarboxylsyraestrar med en polyhalogensubstituent, anvaendbara foer bekaempning av parasiter hos varmblodiga djur.
AR211097A1 (es) Procedimiento para la preparacionde nuevos derivados de 3-(carbamil o tiocarbamil)-sulfamido-piridina-4-sustituida.
IT7830205A0 (it) Derivati di 1,3,4,5-tetraidrobenz-indolo erelativo procedimento per fabbricarli.
NL7713817A (nl) Nieuwe, therapeutisch werkzame piperazinederiva- ten, werkwijzen ter bereiding hiervan en farma- ceutische preparaten die deze verbindingen be- vatten.
NL7709695A (nl) Werkwijze voor de bereiding van 1-chloor-1,1-di- fluorethaan.
NL7613660A (nl) N2-arylsulfonyl-l-argininamiden en de farmaceutisch aanvaardbare zouten ervan.
FI803817A7 (fi) Kefalosporiinijohdannaisia.
AR211170A1 (es) Procedimiento para la preparacion de nuevos derivados de la tetrahidro-1, 5 10, 10a tiazol (3, 4-b) isoquinoleina.
NO151365C (no) Fremgangsmaate for fremstilling av 4-halogen-dihydropyran-derivater.
NL7704710A (nl) Werkwijzen voor de bereiding en toepassing van nieuwe derivaten van n-fosfonomethylglycine.
NO149428C (no) Fremgangsmaate for fremstilling av fysiologisk aktive prostaglandinderivater.
NL7704087A (nl) Basisch gesubstitueerde xanthinederivaten.
NL7803448A (nl) Nieuwe benzothiadiazinederivaten, alsmede farmaceutische preparaten die deze verbindingen bevatten.
DK138498B (da) Analogifremgangsmåde til fremstilling af antibiotikum A204I-derivater eller fysiologisk acceptable kationiske salte deraf.
NL7610150A (nl) 1,5-dihydro-2h-1,4-benzodiazepin-2-on derivaten.
NL7705561A (nl) Farmaceutisch preparaat en werkwijzen voor de bereiding en toepassing ervan.
FI802318A7 (fi) 6-alkyyli-7-fenyyli-1,6-naftyridiini- 5(gH)-oni-johdannaisia.
NL7710325A (nl) Werkwijze ter bereiding van nieuwe chinolinede- rivaten, alsmede werkwijze ter bereiding van farmaceutische preparaten.
NL7806321A (nl) Piperazinecarbodithiozuurderivaten, werkwijze voor de bereiding daarvan en geneesmiddelen daaruit.
IT7822316A0 (it) Composizione farmaceutica per la somministrazione di pancreatina.
NL7513446A (nl) Nieuwe chinoxaline-1,4-dioxyde derivaten en werk- wijze voor hun bereiding.
NL7705444A (nl) Werkwijze voor de bereiding van perfluor-4-oxo- -2,5-dimethyl-2-fluorcarbonyl-1,3-dioxolan.
NL7708845A (nl) 1-aryloxy-3-aminopropan-2-ol derivaten.

Legal Events

Date Code Title Description
ST Notification of lapse